David J Jackson
Overview
Explore the profile of David J Jackson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Couillard S, Jackson D, Pavord I, Wechsler M
Chest
. 2024 Sep;
167(2):330-342.
PMID: 39245321
In this installment of the How I Do It series on severe asthma, we tackle the clinical conundrum of choosing the right biologic for the right patient with severe asthma....
12.
Naftel J, Jackson D, Coleman M, dAncona G, Heaney L, Dennison P, et al.
Lancet Respir Med
. 2024 Aug;
13(1):80-91.
PMID: 39216499
Uncontrolled asthma is associated with an increased risk of adverse perinatal outcomes. Asthma biologics reduce exacerbation frequency, are steroid sparing, and improve quality of life in people with severe asthma....
13.
Rupani H, Busse W, Howarth P, Bardin P, Adcock I, Konno S, et al.
Allergy
. 2024 Aug;
79(10):2589-2604.
PMID: 39087443
The role of eosinophils in airway inflammation and asthma pathogenesis is well established, with raised eosinophil counts in blood and sputum associated with increased disease severity and risk of asthma...
14.
Jackson D, Burhan H, Rupani H, Pfeffer P, Clifton I, Faruqi S, et al.
Clin Exp Allergy
. 2024 Jul;
54(10):734-746.
PMID: 39084909
Background: Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term...
15.
Busby J, Menon S, Martin N, Lipworth J, Zhang R, Burhan H, et al.
J Allergy Clin Immunol Pract
. 2024 Jul;
12(10):2785-2797.
PMID: 39032830
Background: Type 2 low-severe asthma phenotype is often a result of corticosteroid-overtreated type 2 disease owing to persistent symptoms, often unrelated to asthma and unlikely to respond to high-dose corticosteroid...
16.
Hua A, Sularz A, Wheen P, Alam V, Rajani R, Chiribiri A, et al.
JACC Cardiovasc Imaging
. 2024 Jul;
17(10):1261-1264.
PMID: 39001733
No abstract available.
17.
Denton E, Hew M, Peters M, Upham J, Bulathsinhala L, Tran T, et al.
Allergy
. 2024 Jun;
79(10):2700-2716.
PMID: 38923444
Background: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence,...
18.
Tran T, Heatley H, Bourdin A, Menzies-Gow A, Jackson D, Maslova E, et al.
J Asthma Allergy
. 2024 Jun;
17:573-587.
PMID: 38919734
Purpose: Oral corticosteroid (OCS) use for asthma is associated with considerable healthcare resource utilization (HCRU) and costs. However, no study has investigated this in relation to patterns of intermittent OCS...
19.
McDowell P, McDowell R, Busby J, Eastwood M, Patel P, Jackson D, et al.
Eur Respir J
. 2024 Jun;
63(6).
PMID: 38901893
No abstract available.
20.
Rupani H, Edwards D, Chaudhuri R, Smith S, Jackson D, Hearn A, et al.
J Allergy Clin Immunol Pract
. 2024 May;
12(9):2510-2513.e2.
PMID: 38796102
No abstract available.